Correct Steini
"Imugene MD & CEO Leslie Chong said: “Early data arising from our patients dosed at lowlevels with our CF33 oncolytic virus have indicated immune activation is occurring in thetumour microenvironment, turning the tumour from ‘immunologically cold to hot’. This is aperfect time to introduce an immune checkpoint inhibitor such as pembrolizumab (KEYTRUDA).”
This is the environment KEYTRUDA thrives in. The data read-out could be spectacular ... one worth the wait.
Currently, our SP may not look stellar, and this has been discussed ad nauseam, but this trial has the potential to reverse all that.
I'll be watching this one like a hawk. We could very well be getting to the 'pointy end' sooner than many realise. Hold tight.
Opinion only of course.
Correct Steini"Imugene MD & CEO Leslie Chong said: “Early data...
-
- There are more pages in this discussion • 140 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
4.8¢ |
Change
0.000(0.00%) |
Mkt cap ! $357.0M | |||
| Open | High | Low | Value | Volume |
| 4.8¢ | 4.8¢ | 4.7¢ | $379.2K | 7.937M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 21 | 3773908 | 4.7¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 4.8¢ | 1293222 | 7 |
View Market Depth
| Last trade - 16.10pm 12/11/2024 (20 minute delay) ? |
| IMU (ASX) Chart |